Organon & Co. Hits New 52-Week High of USD 13.72

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.72 on August 13, 2026. This achievement marks a notable recovery from its 52-week low of USD 5.69, showcasing the stock's volatility over the past year. Despite the recent uptick, Organon & Co. has experienced a challenging year, with a performance decline of 33.75%, contrasting sharply with the S&P 500's gain of 20.6% during the same period. The company's market capitalization stands at USD 1,520 million, reflecting its position within the small-cap segment. Financially, Organon & Co. presents a price-to-earnings (P/E) ratio of 3.00, indicating a potentially attractive valuation relative to earnings. The company also boasts a return on equity of 69.90%, suggesting effective management of shareholder equity. Additionally, with a dividend yield of 1.02% and a debt-to-equity ratio of 10.78, Organon & Co. maintains a balanced financial structure. This recent price movement highlights the stock's dynamic nature within the competitive pharmaceutical landscape.